Business
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster drug Keytruda®[1] (pembrolizumab), in the Middle East and North Africa ("MENA region"). The agreement includes an option for future technology transfer.
About this update from Formycon Ag
[{"type":"text","content":"PLANEGG-MARTINSRIED, Germany and AMMAN, Jordan, Dec. 4, 2025 /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster drug Keytruda®[1] (pembrolizumab), in the Middle East and North Africa ("MENA region"). The agreement includes an option for future technology transfer.","length":478,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"MS Pharma Logo (PRNewsfoto/MS Pharma Saudi Arabia)","displaySize":"","headline":null,"caption":"MS Pharma Logo (PRNewsfoto/MS Pharma Saudi Arabia)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":126,"url":"https://media.zenfs.com/en/prnewswire.com/da67534656022e675eb66f3688200a0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p0qkQ.agWMZUaezQXqXP_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/da67534656022e675eb66f3688200a0b","width":400,"height":126}},"href":"https://mma.prnewswire.com/media/2759179/MS_Pharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":""This licensing deal for the MENA region represents the start of the commercial partnering activities for our Keytruda® biosimilar candidate. Further agreements for additional regions and countries shall follow in due time. With MS Pharma, we are leveraging the well-established excellent collaboration that has already been successfully implemented for our biosimilars FYB201, FYB202, and FYB203. MS Pharma is a strong player that can sustainably improve access to this important cancer drug across the MENA region. FYB206 is currently approaching the end of its clinical development phase, and we expect results for the primary endpoint in the first quarter of 2026," said Nicola Mikulcik, CBO of Formycon AG.","length":721,"tagName":"p"},{"type":"text","content":""Extending our partnership with Formycon for FYB206 (pembrolizumab), is a strategically important milestone for MS Pharma. This collaboration not only strengthens our position as a leader in biosimilars across the MENA region but also demonstrates our co...